|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/295 | |
| A61P 7/06 | |||
| A61P 13/12 | |||
| A61K 9/28 |
| (11) | Number of the document | 2863906 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13807102.2 |
| Date of filing the European patent application | 2013-06-21 | |
| (97) | Date of publication of the European application | 2015-04-29 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/047134 |
| Date | 2013-06-21 |
| (87) | Number | WO 2013/192565 |
| Date | 2013-12-27 |
| (30) | Number | Date | Country code |
| 201261662565 P | 2012-06-21 | US | |
| 201361757229 P | 2013-01-28 | US | |
| 201361801050 P | 2013-03-15 | US | |
| 201361800618 P | 2013-03-15 | US |
| (72) |
PORADOSU, Enrique, US
BENTSUR, Ron, US
OLIVIERO III, James F., US
|
| (73) |
Keryx Biopharmaceuticals, Inc.,
245 First Street, Suite 1400, Cambridge, MA 02142,
US
|
| (54) | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS |
| USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS |